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ABSTRACT
RNA editing is a post-transcriptional modification of RNA. The majority of these
changes result from adenosine deaminase acting on RNA (ADARs) catalyzing the
conversion of adenosine residues to inosine in double-stranded RNAs (dsRNAs).
Massively parallel sequencing has enabled the identification of RNA editing sites in
human transcriptomes. In this study, we sequenced DNA and RNA from human lungs
and identified RNA editing sites with high confidence via a computational pipeline
utilizing stringent analysis thresholds. We identified a total of 3,447 editing sites
that overlapped in three human lung samples, and with 50% of these sites having
canonical A-to-G base changes. Approximately 27% of the edited sites overlapped
with Alu repeats, and showed A-to-G clustering (>3 clusters in 100 bp). The majority
of edited sites mapped to either 3’ untranslated regions (UTRs) or introns close to
splice sites; whereas, only few sites were in exons resulting in non-synonymous amino
acid changes. Interestingly, we identified 652 A-to-G editing events in the 3’ UTR of
205 target genes that mapped to 932 potential miRNA target binding sites. Several of
these miRNA edited sites were validated in silico. Additionally, we validated several
A-to-G edited sites by Sanger sequencing. Altogether, our study suggests a role for
RNA editing in miRNA-mediated gene regulation and splicing in human lungs. In this
study, we have generated a RNA editome of human lung tissue that can be compared
with other RNA editomes across different lung tissues to delineate a role for RNA
editing in normal and diseased states.

INTRODUCTION

functional consequences [1]. RNA editing was first
discovered in the trypanosome in an mRNA encoded by
the kinetoplastid mitochondria [2]. This phenomenon
was later discovered in the nuclear-encoded mRNAs
in the mammals [3]. There are two types of canonical
RNA editing found in the nuclear mRNAs. One involves
the deamination of Cytidine (C) to Uridine (U) that is
relatively less common and catalyzed by members of
cytidine deaminase (AID/APOEBC) family of proteins [4,

In recent years, the focus of molecular biology has
been radically shifted from the “central dogma” (DNA to
RNA to protein) to encompass the role of modifications of
RNA nucleotides via co- or post-transcription mechanisms
termed “RNA editing”. RNA editing involves alteration
in the sequence of RNA that is derived from DNA. The
diverse type of RNA editing events leads to different
www.impactjournals.com/oncotarget
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5]. The second type and the most prevalent RNA editing
event in mammals involves site-specific deamination of
Adenosine (A) to Inosine (I) in dsRNA that is catalyzed
by adenosine deaminase acting on RNA (ADAR) family
of proteins [6]. The consequence of this base change is the
recognition of inosine as guanosine by the translational
machinery leading to A-to-G editing [6]. In addition, as
inosine base-pairs with cytidine, the structure of RNA can
be altered by ADARs by changing AU base pairing to IU
mis-match [1]. Mammalian ADAR proteins (ADAR1 and
ADAR2) are ubiquitously expressed, whereas ADAR3 is
specifically expressed in the brain [1]. All ten other types
of possible editing events are classified as non-canonical
and are not associated with any known enzymatic
process. Non-canonical events may be an artifact of high
throughput sequencing, and recent studies show a lack of
their validation via Sanger sequencing [7].
RNA editing can occur in either coding or noncoding regions of dsRNA. The site-specific deamination of
adenosine residues in pre-mRNAs can alter the individual
codons resulting in protein diversity. Moreover, ADARs
can edit multiple sites on the same mRNA species
thereby further diversifying the functional outcomes [8].
RNA editing in coding regions may result in recoding
and functional diversification of proteins as seen with
neurotransmitters and ion channels in brain [9-11].
Additionally, RNA editing in introns near a splice site
may affect splicing. Non-coding regions of genes that
are edited include the UTRs [6]. The majority of RNA
editing observed in non-coding regions involve repetitive
elements, such as a long interspersed nuclear element
(LINE) or small interspersed nuclear element (SINE) [12].
However, the biological significance of repetitive element
editing is unknown. In the UTRs, editing by ADARs
can either abolish existing microRNA (miRNA) binding
sites or generate new miRNA target sites owing to seed
sequence differences in miRNA, thereby suppressing a
different set of target genes [13]. RNA editing in ncRNAs
may alter RNA structure or stability, leading to biological
consequences. A-to-I editing of pri- or pre-miRNA by
ADAR1 and ADAR2 inhibits their processing to mature
miRNAs [13]. This information suggests a potential
regulatory role and functional consequence for RNA
editing.
Dysregulation of RNA editing has been linked
to several neurodegenerative diseases such as epilepsy,
amytrophic lateral sclerosis (ALS), depression, brain
ischemia and tumor [8, 14], and human cancers [14-18].
Decreased A-to-I editing has been observed in tumors of
brain, lung, kidney and testis [16]. The highest levels of
ADAR1 transcript are observed in brain and lungs relative
to other tissues [19]. However, unlike brain, the RNA
editome of normal lung has not been well studied. In a
previous study, ADAR1 was shown to be upregulated in a
microvascular lung injury mouse model of inflammation
suggesting a role of RNA editing in pathogenesis of acute
www.impactjournals.com/oncotarget

lung injury [20]. Therefore, we sought to understand
the editome of normal human lungs to later address the
potential role of RNA editing in lung pathogenesis.
With the advent of high-throughput sequencing
(HTS) technology and developmental of computational
tools, it has been possible to identify RNA editing sites
in human and mouse transcriptomes [7, 12, 16, 21-23].
RNA-seq data alone or RNA-seq combined with DNAseq data can be used to identify RNA DNA difference or
RNA editing sites by comparing RNA sequences with the
annotated human reference genomic sequences [24-26].
There are many challenges that are faced by researchers
in the field of RNA editing to call true variants versus
minimizing the identification of false positives in HTS
data [27]. The identification of false positives may be
attributed to sequencing or mapping errors. Conversion
of RNA to cDNA can result in mutation and be a source
of false positive editing sites. Others include errors in
reference genome, paralogous genes, alignment errors at
splice junction sites and introns, identification of SNPs
as editing sites and hard to map heavily edited repetitive
Alu elements or genes that are edited but expressed at low
levels [27]. There are several strategies that can be applied
to overcome identification of false positives in RNA
editing analysis by accurately mapping reads to introns
and splice junctions, applying stringent computational
pipelines, trimming first six base pairs of reads, removing
all known SNPs from the datasets, using RNA and DNA
sequences from the same sample and validating the editing
sites by biochemical or molecular biology techniques [27].
In the present study, we investigated RNA editing in
three normal human lungs using high-throughput (exome)
DNA- and RNA-sequencing data from the same sample
and computational pipeline. We mapped reads to reference
genome and that included all splice junctions and introns
for unique mapping of reads. We used a stringent
computational pipeline to identify RNA editing sites
in three normal lung samples with REDITools software
package [28] (http://150.145.82.212/ernesto/reditools/
doc/) using the criteria: minimum depth of coverage
10X in DNA and RNA, no variant alleles in the DNA
sequencing, at least 2 alternate alleles and at least 10%
alternate alleles in RNA sequencing. These criteria were
based on information available from previous publication
[23]. These criteria led to extraction of RNA editing
sites that overlapped across all 3 samples with the same
substitution. We also removed all possible SNPs from the
data using the dbSNP database.
This study demonstrates that RNA editing is
widespread in normal human lungs, and the majority of
events are canonical A-to-G editing that map to introns
and 3’ UTRs of target genes. We observed few nonsynonymous amino acid changes in target genes as very
few edited sites were found in exons or coding sequence
(CDS) of target genes. Many of the hyper-edited sites
were found in A-to-G clusters. Several of these editing
35727
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sites were validated by Sanger sequencing. Interestingly,
we identified editing within the miRNA binding sites in
3’UTR of candidate genes for normal lung samples and
several miRNA edited sites were validated by in silico
method. Altogether, for the first time, we have generated
an editome of normal human lungs using high-throughput
sequencing technology and computational tools. This
database would serve as an important platform to discern
a role of RNA editing in normal lung biology and its
dysregulation in lung disease.

of which ~98% aligned uniquely to the human reference
genome (hg19). 79% of reads aligned to the targeted
exome giving an exome coverage of 69X. 92% of targeted
bases were covered at 10X coverage and 81% at 20X
(data not shown). For RNA sequencing, we generated an
average of 130 million reads per sample of which ~88%
mapped to the human reference genome (hg19) with
only 5% of the reads mapping to multiple loci (data not
shown). For each lung sample, we identified both the
canonical and non-canonical editing sites by comparing
their own DNA and RNA sequences using REDItools as
previously described [28, 29]. Further filtering was done
using criteria as previously described [23]: 10X minimum
depth of coverage in both DNA and RNA sequences, no
variant alleles in DNA sequencing, and at least 2 alleles
and 10% alternate alleles in RNA sequencing (Figure S1).
We extracted sites that overlapped across all three normal
lung samples with the same base substitutions. We retained
Alu sequences in our analysis as they represent potential
sites of ADAR-mediated editing [22]. Previously, several
groups have identified RNA editing event in human tissues
using only RNA-seq data alone without the DNA sequence

RESULTS AND DISCUSSION
RNA-sequencing and whole exome analysis of
lung tissue
We sequenced DNA (exome plus UTRs) and
RNA from three normal human lung samples using the
Hiseq2500 platform (Illumina). For DNA sequencing,
we generated an average of 110 million reads per sample

Figure 1: Identification of RNA editing sites in normal lung samples. A. Both canonical (A-to-G) and all other types of non-

canonical events that overlapped between all three normal lung samples are shown. B. Genomic distribution of all overlapping RNA editing
types in the three normal human lung samples. C. Venn diagram showing the overlap between edited sites identified in our analysis and
DARNED.
www.impactjournals.com/oncotarget
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information and developed various computational pipeline
to minimize the detection of false positive editing sites
in their datasets [12, 16, 21, 22, 26, 30, 31]. As of now,
there is no fool- proof single computational tool that is
most appropriate in detecting RNA editing sites with high
confidence. We acknowledge that comparison between
different platforms is difficult to make an argument as to
which is the best computational tool for editing analysis.
However, RediTools is widely used tool for studying RNA
editing either using RNA-seq data alone or both RNAseq and DNA-seq data. The software has various filters
to minimize biases resulting from sequencing errors,
mapping errors, and SNPs [28].
At 10X coverage, we identified 5,538 edited sites
that were present in all the three lung samples, and of
these 2,805 edited sites were A-to-G, 344 were C-to-T
and 2,389 were all other types of base substitutions. For
more confident filtering of edited sites, we used 20X
coverage and 20% alternate RNA allele frequency and
identified 3,447 sites that were present in the three human
lung samples. These included both canonical editing
sites (1,856 A-to-G and 226 C-to-T) and all other types
(1,365) of non-canonical editing sites (Figure 1A). We
report 50% (1,856/3,447) of canonical A-to-G editing
sites in our lung dataset, which correlate well with other
published reports that used high-throughput human
sequencing data from various tissues or cells [21-23]. In
addition to the overlapping editing sites, we also found
1,480, 1,594 and 1,853 unique A-to-G editing events in
each of the three human lung samples, respectively; this
implies that within normal human lung samples, there is
some degree of heterogeneity with respect to the editing
events. Previously, the ENCODE project utilized RNAseq data only to identify 50-85% of RNA variants (A-to-G
substitutions) in 14 human cell lines. An important finding
from this project is that although the list of genes with
the edited sites overlapped between different cell lines,
the individual sites that were edited varied, implying
tissue-specific editing events. In the ENCODE project,
a total of 1,322 RNA variants were identified in normal
human lung fibroblasts (NHLF) and 80% of these were
A-to-G base changes. We identified 1,856 A-to-G base
changes in normal human lung tissues using both RNA
and DNA sequencing data after filtering for SNPs. These
datasets suggest that there could be a difference in celltype-specific editing in lungs, although this cannot be
discerned from currently available public data. There are
several steps inherent to identification of RNA editing
sites by high throughput sequencing that can result in false
positive results. These include molecular events, such as
the introduction of variants by RNA to cDNA conversion,
and bioinformatic events such as misalignment, mapping
errors in paralogous genes, and rare reference variants that
appear as edited events. We have adopted several steps,
suggested by Bass et al., 2012, to reduce false positives.
First, we have sequenced RNA and DNA from the same
www.impactjournals.com/oncotarget

tissues removing the possibility that rare DNA variants
are interpreted as editing events. Secondly, we have
adopted a strict two-pass alignment strategy adopted as
the GATK best practice for calling sequencing variants
from RNA (https://www.broadinstitute.org/gatk/guide/
article?id=3891). Finally, we have utilized a strict heuristic
filter to reduce false positive including coverage of at
least 20X, 20% alternate allele frequency, and absence of
the site in the DNA sequencing. Identification of a vast
majority of canonical A>G editing sites suggests that
overall false positive rates are low as reported in a recent
paper [12]. While we have not directly calculated the false
discovery rate in our data, we believe it to be as good as or
better than previously published estimates.
The profiling of a RNA editome of a lymphoblastoid
cell line, which was derived from a single human
individual using RNA-seq data, led to the identification
of 22,688 editing events. Majority (21,099) were A-to-G
editing events, and the rest were all other types of noncanonical editing events [22]. In a recent study [23],
RNA-DNA differences identified in a B-lymphoblast
cell line derived from two humans subjects revealed
approximately 10,000 overlapping A-to-G editing events.
Using a similar approach, we identified 1,856 A-to-G
overlapping editing sites in normal human lung tissues.
This disparity in the number of editing sites may be due
to the editing levels in cultured B-lymphocytes relative to
lung tissue, and heterogeneity of lung tissues compared to
the homogenous B-lymphocyte culture. In another largescale deep-sequencing study [31], 5,965 out of a total
of 9,636 editing sites were identified as putative A-to-G
events. In our study, we identified 1,856 A-to-G editing
events in normal human lung tissue. The variation in
results among published studies may be due to a number
of factors including the use of differing analysis pipelines
and filters, study designs, sequencing depth or coverage,
distribution of editing sites, and extent of transcriptome
analyzed. Re-analysis of a controversial published data
[32] by another group lead the authors to conclude that
large number of sites called positive for editing were
not validated by their analysis [33]. From these studies
we can conclude that there is a need for the development
of a common analysis with stringent filtering criteria to
facilitate comparisons across different editome analyses
and avoid identification of false positive editing sites. In
addition, there is a need to validate the editing sites by
molecular biology and biochemistry techniques in vitro
instead of relying completely on computational analysis
alone. Similar to human studies, RNA-editing analysis
in different tissues of mice identified 242 A-to-G editing
events. All other non-canonical editing sites (683) were
shown to be an artifact of the sequencing reaction [7].
Taken together these studies support the view that a large
proportion of editing events in mammals are canonical
A-to-G base changes.

35729
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Genomic distribution of canonical and noncanonical editing sites in lungs

edited sites out of a total of 2,805 from our (REDItoolsgenerated) dataset in DARNED (Figure 1C). Therefore,
2,050 (73.08%) editing sites are uniquely identified from
the analysis of our lung data. DARNED contains a total of
333,215 editing sites, 220,604 (66.20%) of those sites are
unique A-to-G type. Hence, our dataset identified 0.34%
(755/220,604) of the unique A-to-G DARNED sites.
The low percentage of edited sites that overlapped with
DARNED is significant considering that DARNED is not
enriched for lung-specific genes. This is in concordance
with previous publications wherein a low percentage of
edited sites were shown to overlap with DARNED [22,
34]. Taken together, this information suggests that some
edited sites may be present in all tissues but the majority
of ADAR-mediated editing may be tissue or cell-specific.
Moreover, ADAR may target the same transcript at
different positions in a tissue or cell-dependent manner.
As we were interested in only ADAR-mediated canonical
editing, we further studied the ADAR-specific targets in
the lung.

Further analysis of all overlapping canonical (1,856
A-to-G and 226 C-to-T) and non-canonical editing (1,365)
events in lung tissue at 20X coverage and 20% alternate
alleles revealed enrichment in the 3’ UTR and introns
of genes consistent with previous findings. Conversely,
the coding sequences represented only a small fraction
of edited sites in the target genes that is consistent with
previous reports [22, 23]. In our datasets around 1,050
sites ( 30%) mapped to introns, 968 sites (28%) to 3’
UTR, 138 sites (4.0%) to exons, 120 sites (3.5%) to
coding sequences (CDS), and 1,130 edited sites (32.78%)
could not be assigned to any gene by annotation and
represent unknown editing events (Figure 1B). In a recent
study, RNA editing sites in brain, thyroid, lung, heart and
skeletal tissue (tissue specific editing, TSE) were found to
be enriched in 3’ UTR of genes [30]. This is in agreement
with our analysis of lung editome showing enrichment of
editing sites in 3’ UTR of genes. In our dataset, only 8 out
of 200 (4%) overlapping editing sites in exons resulted
in a non-synonymous amino acid change. The A-to-G
editing in Dcp2, Pms2, Senp3, and Znf551 resulted in nonsynonomous amino acid change.
In the ENCODE project, the A-to-G editing sites
in the lymphoblastoid cell line similarly mapped to
introns (51%) and 3’UTRs (39%) as observed in our
dataset; whereas in the non A-to-G editing sites, there
was a 82% enrichment near splicing boundaries [21].
Similar to Peng et al. (2012), we found that the sites
in the transcripts were edited to varying levels in both
coding and non-coding regions. We observed that genes
with single or multiple edited sites mostly mapped to
either 3’ UTR or introns relative to exons or CDS. We
also found that at 10X coverage, 1,517 (27%) sites out
of 5,538 overlapped with Alu-rich regions of genes.
Consistent with previous published observations [22, 23],
the A-to-G base changes at multiple sites were enriched
in sequences that significantly overlap with Alu and LINE
or SINE elements. An interesting feature of the edited
sites in the target genes in our dataset was the A-to-G site
clusters (30% of sites patterned in >3 clusters in 100 bp).
This is in concordance with previous reports [22, 34] but
substantially differs from what is reported (85%) in the
DAtabase of RNA Editing (DARNED) [35]. DARNED
database is a database of RNA editing in humans. It
provides centralized access to all publications related to
RNA editing. The latest release contains 333,215 edited
sites, of which 221,595 are A-to-G edited sites. The
database contains information on the tissue, organ or cell
wherein the editing has been observed, the gene that is
edited, the co-ordinates and information on the SNPs.
We further compared the sites that were edited in our
dataset with editing sites in DARNED (http://darned.
ucc.ie/download) [35]. We found 755 (26.92%) A-to-G
www.impactjournals.com/oncotarget

Characterization of ADAR-specific target sites in
lungs and pathway enrichment of edited genes
For the functional characterization of target sites, we
focused on A-to-G canonical editing events in lung tissue
that are likely to be mediated by ADARs. We mapped
the edited sites that overlapped in all three normal lung
samples to identify 513 unique genes with at least one
edited sites at 20X coverage. We have listed all the genes,
the chromosomal region showing the edited sites, type
of editing and genomic location in Table S1. It is evident
from Table S1 that 24 (2.61%) of the 513 genes are hyperedited - having 10 or more editing sites; whereas the rest of
the genes have < 10 edited sites. To discern the functional
role of ADAR1 or ADAR2, the future studies will address
the effect of ADAR1/ADAR2 knockdown on editing in
lung fibroblasts derived from normal human lungs.

Identification of RNA edited sites by REDItools
analysis
Editing sites in genes were analyzed using
Integrative Genomics Viewer (IGV). The edited sites in
Ctsc, RhoA and Adam19 were visualized by IGV (Figure
2A). IGV images reveal editing sites (C) only in the
RNA-seq trace (upper panel) and not in the corresponding
genomic trace (lower panel). These represent putative
editing sites (in negative strand) (Figure 2A).

Validation of edited sites by Sanger sequencing
To validate our findings in vitro, we randomly
selected (A-to-G) canonical editing sites comprising both
35730
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hyper- and single-edited sites in the 3’ UTR regions of
genes for Sanger sequencing. For the hyper- or singleedited sites, we PCR amplified 400bp region flanking
the edited sites using specific primers tagged with M13
sequence to amplify both genomic DNA and cDNA.
Sanger sequencing was performed for each PCR-amplified
product (Genomic and cDNA) using both forward and
reverse M13 primers for all three lung samples resulting
in a total of twelve sequences per transcript. These
sequence files (AB-1) were aligned and further analyzed
using Sequencher 5.1 software (Gene Code Corporation).
We validated several canonical editing sites in all three
lung samples in vitro by Sanger sequencing. We show
representative images for Ctsc, RhoA and Adam19,
respectively (Figure 2B). The genomic and cDNA trace
of the edited sites for each gene is shown (Figure 2B).
For Ctsc, we show three edited sites (chr11:88,055,689
to 88,055,691). For RhoA, we validated A-to-G editing
at a single site (chr3:49,397,323). Similarly, for Adam19,
we confirmed A-to-G editing at five different sites

(chr5:156,905,556 - 156,905, 568). For sites that were
validated, an “A” (un-edited reference peak) in the
genomic trace and two peaks in cDNA trace, namely
an “A” (un-edited reference peak) and a “G” (edited
peak) were observed in the positive strand (Figure 2B).
Taken together, these results indicate true editing events
occurring in normal human lung tissue, and, most
interestingly, the canonical edited sites are located in the
non-coding regions of the genes.
For pathway analysis, we further filtered 513 edited
genes by selecting all genes in the overlap with at least
one 3’ UTR editing site and this resulted in 336 genes
in the dataset. We performed gene set enrichment using
MetaCore and BinGo. Interestingly, lung-specific editing
sites were found in genes related to Apoptosis and cell
survival, cytoskeleton remodeling, ER stress response
pathway, Granzyme B signaling, TGF-beta, Wnt and Erk
signaling (Table S2). This is contrast to a study wherein
they found lung-specific editing sites enriched in genes
related to signal peptide processing and response to

Figure 2: Validation of A-to-G editing by Sanger sequencing. A. Integrative Genome view of Ctsc, RhoA and Adam19 is shown.

The RNA- and DNA-seq traces are shown in top and bottom panel, respectively. B. Validation of editing sites in Ctsc, RhoA and Adam19
is shown. For Ctsc, three editing sites were validated (chr11:88,055,689, 88,055,690, 88,055,691). For RhoA, we validated one site
(chr3:49,397,323). For Adam19, we validated five sites chr5: (156,905,567, 156,905,566, 156,905, 565 in the left panel and 156,905,561,
and 156,905,560) in the right panel. The sites validated by Sanger are shown and the nucleotide changes are labelled. Samples were
sequenced using both forward and reverse M13 primers. We show few representative images of each.
www.impactjournals.com/oncotarget
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viral or inflammatory stimuli [30]. Gene ontology (GO)
revealed enrichment of several metabolic processes (Table
S3). The small number of genes that are enriched in these
pathways suggests that the edited events may not be
pathway specific but represent similar genes that are edited
in the overlapping dataset and may thus represent baseline
editing in normal human lungs.

miRanda [37] . Using Ensembl BioMart (GRCh37), each
transcript with only one validated 3’ UTR start site had
its position reported. For each of those transcripts, the
BioMart-reported 3’ UTR start position was added to
the miRanda-reported RNA start and end coordinates to
obtain the miRNA target locations. We then parsed the
generated miRNA target locations to determine if the
previously identified RNA edited sites existed within
those boundaries. As we were interested in only A-to-G
canonical editing sites, we filtered for those events and
generated a list of genes containing A-to-G editing
in miRNA targets (Figure 3A). For all chromosomes
analyzed, we found a total of 652 editing events in 933
potential miRNA target binding sites that mapped to 205
candidate genes (Figure 3A). From Figure 3A, it is evident
that miRNA sites in various chromosomes are edited
differentially. The most logical explanation is that these
target genes are differentially regulated in the three normal
human lung samples. The data on the miRNA binding sites
in the target genes that are edited, and the chromosomal

Role of RNA editing in miRNA-mediated
regulation of candidate genes
Given that the majority of edited sites identified
in the lung samples were in the 3’ UTR of the candidate
genes, we were interested in determining if these sites
were located within miRNA target sites. The potential role
of RNA editing in miRNA-mediated gene silencing has
been previously described [13, 36]. We identified potential
human miRNA target sites (energy < -20 and score > 155)
associated with Ensembl (GRCh37) transcripts using

Figure 3: Identification of RNA editing in miRNA target binding sites in the 3’ UTR of genes. A. Genes containing A-to-G

edited miRNA targets for all chromosomes are shown. On the x-axis, the chromosome number, total number of editing events, and total
number of miRNA targets associated with it are listed. On the y-axis, the number of genes associated with editing events in the miRNA
binding sites is depicted. B.-C. Validation of editing in potential miRNA binding sites by in silico analysis for Rbbp4 B. and Spcs3 C.
The images show miRNA target sites and the complementary hg19 sequence. The edited site in the seed sequence of the mature miRNA
is highlighted in bold. The hsa-miR-6849-3p binding site was located in Rbbp4 3’ UTR at chr1:33,149,343-586. The bold position is an
A-to-G RNA-editing event located at chr1:33,149,443 in Rbbp4 (B). Similarly the hsa-miR-1303 binding site is located in Spcs3 3’ UTR at
chr4:177,252,226-427. The bold positions are two A-to-G edited sites located at chr4:177,252,326 and 327 (C).
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

location are shown in Table S4. As shown in Table S4,
multiple miRNA binding sites are edited for majority of
genes relative to single edited site. Considering that we
identified 513 candidate genes that were edited in all
three lung samples, 39.96 % (205/513) of candidate genes
have miRNA binding sites edited in their 3’ UTRs. In a
previous study [22], 20.89% of the edited sites that resided
in the 3’ UTR were reported to alter the miRNA target
sites. In another study [38], RNA editing was identified
in 6% of human miRNA and was proposed to affect the
miRNA processing possibly resulting in altered target
recognition and increased miRNA diversity. Nevertheless,
the functional consequence or biological significance of
altered miRNA target sites (single or hyperedited) on gene
expression remains to be addressed. From the literature, it
is apparent that in human transcriptome, majority of sites
(>85%) are hyper-edited in Alu repeats. Alu elements
have been shown to modulate gene expression at posttranscriptional level. These repetitive elements easily form
double stranded structures and provide ideal substrate that
is amenable to editing by ADAR enzymes. Several groups
have used HTS and computational pipeline with stringent
filtering to identify A-to-G editing in Alu repeats [24-26].
Site-specific editing in introns may affect splicing or in
codons, alter the amino acids composition and thereby
increase protein diversity. In the 3’ UTR, site-specific
RNA editing can alter miRNA binding sites thus affecting
gene expression [6].
We randomly selected few miRNA target sites in
genes and validated the alteration in the miRNA binding
sites (within 2nd to 8th nucleotide of the seed region of
mature miRNA) by an in silico approach using miRanda.
As an example, we show the A-to-G editing in the miRNA
binding sites for two genes Rbbp4 and Spcs3 (Figure
3B-3C). For Rbbp4, hsa-miR-6849-3p binding site is
located in chr1 between the positions 33,149,343-586 in
the 3’ UTR of the gene. The miRNA sequence is shown
at the top and the complementary hg19 region is shown
below. The A-to-G editing site mapped to chr1:33,149,443
(7th nucleotide of the seed) (Figure 3B). Similarly, for
Spcs3, we identified hsa-miR-1303 binding site in
chr4:177,252,226-427 in the 3’ UTR of the gene (Figure
3C). The A-to-G edited sites mapped to chr4:177,252,326
(1st) and 327 (2nd) within the seed sequence (Figure 3C).
In summary, we have generated an editome
of normal lung tissue that defines the RNA variants
overlapping in three samples using (exome) DNA- and
RNA-sequencing data and REDItools RNA editing
analysis. In future studies, we will adapt this methodology
to interrogate large datasets of lung tissues to generate a
RNA editome of normal and diseased samples. Profiling
the RNA editome will assist in understanding the role of
RNA editing in both normal and diseased states, and will
be a novel approach to understanding the molecular basis
of lung pathogenesis.

www.impactjournals.com/oncotarget

Ethics statement
This study was reviewed and approved by the
Institutional Review Board (IRB) of the University of
South Florida.

Human samples
De-identified normal human lung tissues (N=3)
collected from peripheral regions of lungs from deceased
individuals, 40-60 yrs of age ( 2 males and 1 female) were
obtained from National Disease Research Interchange
(NDRI), Philadelphia, PA. These “normal human lung”
tissues refer to the samples obtained from non-diseased
individuals.

Sample preparation
Genomic DNA was extracted from three
normal human lung samples using DNeasy kit as per
manufacturer’s instructions (Qiagen). Total RNA was
extracted from three normal human lung samples using
Trizol reagent (Life Technologies) combined with RNeasy
kit as per manufacturer’s instructions (Qiagen). To prevent
genomic DNA contamination of RNA, we treated RNA
samples to on column DNase digestion according to
manufacturer’s instructions (Qiagen). Quality control
for both genomic DNA and RNA was carried out using
Agilent 2100 Bio-analyzer at the Center for Genomic
Technology (CGT), John P. Hussman Institute for Human
Genomics at the University of Miami Miller School of
Medicine.

Massively parallel sequencing
Massively parallel sequencing (whole exome
sequencing and RNA sequencing) was performed at the
CGT. DNA-seq libraries for three normal human lung
samples were prepared with Agilent Xt reagents and
captured with the Agilent SureSelect 50MB + UTR exome
V5 sample kit. RNA-seq libraries were prepared for three
normal human lung samples using the Epicenter Ribozero
ScriptSeq-v2 RNA prep kit (Illumina). All samples were
sequenced 3 per lane with paired end 100bp reads on a
HiSeq2500 (Illumina).
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(http://lsresearch.thomsonreuters.com/pages/solutions/1/
metacore) and CytoScape BinGo ( http://www.psb.ugent.
be/cbd/papers/BiNGO/Home.html).

DNA alignment and variant calling

Validation of
sequencing

DNA reads were processed according to Genome
Analysis Toolkit (GATK) best practices. DNA reads were
aligned to the human hg19 (GRCh37) genome with bwa
and exome enrichment statistics calculated with PICARD.
DNA variants were called with the GATK Unified
Genotyper for each individual exome sample. Variants
were filtered for sites at a minimum depth of 8X and PL
score > 100 for alternate alleles. We used ANNOVAR for
annotation and included annotation from RefGene, dbSNP,
frequency in the Exome Variant Server (EVS), frequency
in 1000 Genome project, and frequency in the Exome
Aggregation Consortium (ExAC).

using

Sanger

DNA and RNA were isolated from normal human
lungs as described previously. Total RNA was reverse
transcribed to yield cDNA using iScript RT (Biorad) and
random primers as per the manufacturer’s instructions
(Biorad). PCR was carried out using primers that were
designed flanking the editing sites to amplify at least a
400 bp product. Primers were designed such that they
could be used on both genomic DNA (gDNA), and spliced
cDNA. We also tagged primers with M13 primers at the
end so that it could be amenable to Sanger sequencing
using M13 primers alone. Amplified PCR products were
purified using PCR purification kit (Qiagen) and subjected
to Sanger sequencing using M13 primers at both ends
using standard protocol at Moffitt Genomics facility.
The potential edited sites were considered validated
if the cDNA sequence at the edited site contained two
peaks, (both a reference peak and an edited peak) but the
corresponding gDNA contained only one reference peak.
Sites were considered to be un-validated if it contained
only a single reference peak in both cDNA and gDNA
traces.

RNA Alignment
RNA reads were processed for variant calling
according to the GATK best practices including quality
and adapter trimming with TrimGalore, alignment in a
2-pass alignment with the STAR aligner to the human
genome hg9/GRCh37, and base quality recalibration.

Identification of RNA editing sites with REDItool

Identification of editing sites in the microRNA
target site

We used the REDItools software package to
create tables of every potential RNA editing position
(http://150.145.82.212/ernesto/reditools/doc/) [28]. We
required: minimum depth of coverage 10X in DNA and
RNA, no variant alleles in the DNA sequencing, at least
2 alternate alleles and at least 10% alternate alleles in
RNA sequencing based on previous publication [23].
These criteria led to extraction of RNA editing sites that
overlapped across all 3 samples with the same substitution.
Annotation of each editing sites in the selected files
was achieved by using the Human RefSeq database.
Confidence filtering for edited sites was achieved by
using stringent conditions such as 20% alternate RNA
allele frequency and 20x RNA coverage. Feature and Gene
based counting of edited site in the genomic locations such
as intron, exon, CDS, 3’ UTR, 5’ UTR, or unknown sites
were identified based on RefSeq annotations [39].

A list of potential human miRNA target sites
were derived from Ensembl (GRCh37) transcripts using
miRanda [40]. miRNA targets were filtered using energy
< -20 and score > 155 thresholds. Using Ensembl BioMart
(GRCh37), each transcript with only one validated
3’ UTR start site had its position reported. For each of
those transcripts, the BioMart-reported 3’ UTR start
position was added to the miRanda-reported RNA start
and end coordinates to obtain the miRNA target locations.
The generated miRNA target locations were parsed to
determine if the previously identified RNA edited sites
existed within those boundaries.

DATA DEPOSITION

Pathway/network analysis

The RNA-seq data and DNA-seq data are deposited
within Short Read Archive (SRA) under accession number
SRP061159. This is the site where the FASTQ files will be
made publically available.

For the pathway/network analysis, we first identified
all the genes that overlapped in the three normal human
lung samples that contained at least one editing site in
the 3’ UTR. This resulted in a total of 336 genes. We
performed gene enrichment analysis using MetaCore
www.impactjournals.com/oncotarget
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